Cargando…

Contrast-induced nephropathy in patients with chronic kidney disease and peripheral arterial disease

BACKGROUND: The risk for contrast-induced nephropathy (CIN) after intra-arterial application of an iodine-based contrast material is unknown for patients with chronic kidney disease (CKD) and peripheral arterial disease (PAD). PURPOSE: To investigate the incidence of CIN in patients with CKD and PAD...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroneberger, Christian, Enzweiler, Christian N, Schmidt-Lucke, Andre, Rückert, Ralph-Ingo, Teichgräber, Ulf, Franiel, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548732/
https://www.ncbi.nlm.nih.gov/pubmed/26346218
http://dx.doi.org/10.1177/2058460115583034
Descripción
Sumario:BACKGROUND: The risk for contrast-induced nephropathy (CIN) after intra-arterial application of an iodine-based contrast material is unknown for patients with chronic kidney disease (CKD) and peripheral arterial disease (PAD). PURPOSE: To investigate the incidence of CIN in patients with CKD and PAD. MATERIAL AND METHODS: This retrospective study was approved by the local ethics committee. One hundred and twenty patients with 128 procedures (73 with baseline eGFR in the range of 45–60 mL/min/1.73m(2), 55 with eGFR < 45 mL/min/1.73m(2)) were evaluated. All patients received intra-arterially an iodine-based low-osmolar contrast material (CM) after adequate intravenous hydration with isotonic NaCl 0.9% solution. CIN was defined as an increase in serum creatinine of more than 44 μmol/L within 4 days. The influence of patient-related risk factors (age, weight, body mass index, eGFR, serum creatinine, hypertension, diabetes mellitus, coronary heart disease, heart failure) and therapy-related risk factors (amount of CM, nephrotoxic drugs, number of CM applications) on CIN were examined. RESULTS: CIN developed in 0% (0/73) of procedures in patients with PAD and an eGFR in the range of 45–60 mL/min/1.73m(2) and in 10.9% (6/55) of procedures in patients with an eGFR <45 mL/min/1.73m(2). No risk factor significantly influenced the development of CIN, although baseline serum creatinine (P = 0.06) and baseline eGFR (P = 0.10) showed a considerable dependency. CONCLUSION: Patients with an eGFR in the range of 45–60 mL/min/1.73m(2) and PAD seem not at risk for CIN after intra-arterial CM application and adequate hydration. Whereas, an eGFR < 45 mL/min/1.73m(2) correlated with a risk of 10.9% for a CIN.